Sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth ...

The company predicted operating profit for 2025 to climb between 19% and 27%, compared to growth of 26% last year.

Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...

Its a healthy morning as Novo Nordisk says sales of its obesity drug, Wegovy, rose 57% last year while Brits are buying more ...

Theme parks have been a concern for analysts, amid signs that U.S. consumer spending is on the wane.

Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose ...

Novo Nordisk reported better-than-expected fourth quarter profit on the back of surging demand for its Wegovy weight loss drug but also said 2025 sales growth would slow slightly as competition for ...

Ozempic, which accounts for 41% of the company's sales, is an injectable anti-diabetic treatment that became wildly popular ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.

Wegovy maker Novo Nordisk has today forecast sales would grow at a slower rate this year although the outlook was roughly in ...